; or (ii) a manufacturer to enter into a value-based purchasing arrangement with a State for a covered outpatient drug; (B) prohibiting a manufacturer from treating a value-based purchasing arrangement as a bundled sale; or (C) precluding the execution of a supplemental rebate agreement, as provided in section 1927(a)(1) of the Social Security Act ( 42 U.S.C. 1396r–8(a)(1) ), for a covered outpatient drug sold under a value-based purchasing arrangement. (c) Definition of average manufacturer price Section 1927(k)(1) of the Social Security Act ( 42 U.S.C. 1396r–8(k)(1) ) is amended— (1) in subparagraph (B)(i)— (A) in subclause (IV), by striking at the end and ; (B) in subclause (V), by striking the period at the end and inserting ; and ; and (C) by adding at the end the following new subclause: (VI) in accordance with subsection (b)(3)(A)(vi), with respect to such covered outpatient drug that is sold under a value-based purchasing arrangement (as defined in paragraph (12)) during the rebate period— (aa) a refund, rebate, reimbursement, or free goods from the manufacturer or third party on behalf of the manufacturer; or (bb) the withholding or reduction of a payment to the manufacturer or third party on behalf of the manufacturer; that is triggered by a patient who fails to achieve outcomes or measures defined under the terms of such value-based purchasing arrangement during the period for which such agreement is effective.